ArticleAbdominal radiology (New York)2022
Comparison of the diagnostic accuracy and validity of biparametric MRI and multiparametric MRI-based VI-RADS scoring in bladder cancer; is contrast material really necessary in detecting muscle invasion?
Article in Abdominal radiology (New York), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05783271 (Validity of Parametric MRI Using VIRAD Scoring in the Diagnosis of Cancer Bladder), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Validity of Parametric MRI Using VIRAD Scoring in the Diagnosis of Cancer Bladder
Who cites it
14 citing papers in PubMed, 36 citations in OpenAlex.
- Decision tree models combining Bi-parametric vesical imaging reporting and data system and apparent diffusion coefficient metrics for predicting muscle-invasive bladder cancer.Abdominal radiology (New York) · 2026Article
- Added value of synthetic MRI in refining biparametric MRI VI-RADS for predicting muscle-invasive bladder cancer.Abdominal radiology (New York) · 2026Article
- Enhancing the performance of BP-MRI VI-RADS in detecting muscle-invasive bladder cancer: the potential role of supplementary quantitative parameters.Japanese journal of radiology · 2026Article
- bp-VI-RADS combined with normalized apparent diffusion coefficient enhances diagnostic efficacy for muscle-invasive bladder cancer.Quantitative imaging in medicine and surgery · 2026Article
- Predicting variant histology in bladder cancer: the role of multiparametric MRI and vesical imaging-reporting and data system (VI-RADS).Abdominal radiology (New York) · 2025Article
- Comparative diagnostic performance of VI-RADS based on biparametric and multiparametric MRI in predicting muscle invasion in bladder cancer.BMC medical imaging · 2025Article
- Evaluating biparametric MRI for diagnosing muscle-invasive bladder cancer with variant urothelial histology: a multicenter study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Comparison of staging MRI to re-resection for localised bladder cancer: Narrative review.BJUI compass · 2024Review
- Progress of Multiparameter Magnetic Resonance Imaging in Bladder Cancer: A Comprehensive Literature Review.Diagnostics (Basel, Switzerland) · 2024Review
- The role of gadolinium-based contrast agents in magnetic resonance imaging structured reporting and data systems (RADS).Magma (New York, N.Y.) · 2024Review
- Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Novel utility of Vesical Imaging-Reporting and Data System in multimodal treatment for muscle-invasive bladder cancer.European radiology · 2023Review
- 1.5-T MR relaxometry in quantifying splenic and pancreatic iron: retrospective comparison of a commercial 3D-Dixon sequence and an established 2D multi-gradient echo sequence.European radiology · 2023Article
- Comparison between biparametric and multiparametric MRI in predicting muscle invasion by bladder cancer based on the VI-RADS.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose(1) To evaluate the accuracy and validity of the biparametric MRI (bp-MRI), including T2-weigthed image (WI) and DWI sequences, and the availability of an alternative to the multiparametric MRI (mp-MRI), for the muscle-invasiveness assessment of bladder cancer (BC). (2) To evaluate the diagnostic performance and agreement of readers with different experiences in the abdominal imaging of using both protocols.
methodsPreoperative bladder mp-MRI was performed on 128 patients with a initial diagnosis of BC. Two sets of images, set 1 (bp-MRI) and set 2 (mp-MRI), were independently evaluated by both readers. Descriptive statistics, including sensitivity, specificity, accuracy, and area under the curve (AUC), for VI-RADS scores were calculated using ≥ 4 as the cutoff for muscle invasion for each reader and image sets. Inter-reader agreement was evaluated using the Cohen's kappa coefficient.
resultsThe sensitivity ranged between 90.3-93.5% and 87.1-90.3%, specificity ranged between 96.6-99.1% and 91.6-96.6%, accuracy ranged between 96-97.3% and 91.3-94.6%, and AUC ranged between 0.947-0.951 and 0.919-0.921, for bp-MRI and mp-MRI, and reader 1 and reader 2, respectively. No significant differences were shown in diagnostic performance for either reader between both the protocols (p = 0.238 and 0.318). There was excellent agreement among the readers in the VI-RADS scores, using both protocols.
conclusionA bp-MRI protocol has a diagnostic accuracy comparable to an mp-MRI protocol for the detection of muscle-invasive BC using the VI-RADS criteria. Also, in both MRI protocols, the reader's experience does not appear to significantly affect diagnostic performance when using the VI-RADS criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.